IP Library Granted Patent US 11,564,982
Granted Patent B2
US 11,564,982 · App. 16/475,656 · Granted Jan 31, 2023

DNABII vaccines and antibodies with enhanced activity

Inventors: Lauren O. Bakaletz (Hilliard, OH); Steven D. Goodman (Hilliard, OH)
Assignee: Research Institute at Nationwide Children's Hospital
A61K39/102A01N63/50A61K45/06A61P31/04C07K14/285C07K16/1242G01N33/56911A61K38/00A61K2039/505C07K2317/20C07K2317/24C07K2317/55C07K2319/00G01N2333/285
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,564,982
App. No.
16/475,656
Granted
Jan 31, 2023
Kind
B2
Abstract

The disclosure provides methods and compositions that are useful to lessen and/or cure bacterial biofilms and treat diseases or disorders associated with biofilms using one or more novel polypeptide vaccines, antibodies, antibody fragments and compositions. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

Claims (25)

1. A recombinant polypeptide consisting of the polypeptide of SEQ ID NO: 50.

2. A vaccine composition comprising an effective amount of the recombinant polypeptide of claim 1 and a pharmaceutically acceptable carrier.

3. The vaccine composition of claim 2 , further comprising one or more of an adjuvant, a preservative, a stabilizer, at least one antibiotic or an additional active ingredient.

4. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 3 .

5. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of a polypeptide of claim 1 .

6. A recombinant polypeptide comprising the peptide of SEQ ID NO: 12 (FLEEIRLSLESGQDVKLSGF) and the peptide of SEQ ID NO: 15 (TLSAKEIENMVKDILEFISQ) joined via a linker polypeptide comprising the peptide of SEQ ID NO: 44 (GPSL).

7. A composition comprising an effective amount of the recombinant polypeptide of claim 6 and a pharmaceutically acceptable carrier.

8. The composition of claim 7 , further comprising one or more of an adjuvant, a preservative, a stabilizer, at least one antibiotic or an additional active ingredient.

9. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of a vaccine composition of claim 2 .

10. A recombinant polypeptide comprising the peptide of SEQ ID NO: 13 (RPGRNPKTGDVVPVSARRVV) and the peptide of SEQ ID NO: 17 (FSLHHRQPRLGRNPKTGDSV).

11. The recombinant polypeptide of claim 10 , wherein the peptide of SEQ ID NO: 13 and the peptide of SEQ ID NO: 17 are joined via a linker polypeptide comprising the peptide of SEQ ID NO: 44 (GPSL).

12. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of a polypeptide of claim 11 .

13. A vaccine composition comprising an effective amount of the recombinant polypeptide of claim 10 and a pharmaceutically acceptable carrier.

14. The vaccine composition of claim 13 , further comprising one or more of an adjuvant, a preservative, a stabilizer, at least one antibiotic or an additional active ingredient.

15. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 14 .

16. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 13 .

17. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of a polypeptide of claim 10 .

18. A recombinant polypeptide comprising the polypeptide of SEQ ID NO: 50.

19. A composition comprising the polypeptide of claim 18 and a pharmaceutically acceptable carrier.

20. The composition of claim 19 , further comprising one or more of an adjuvant, a preservative, a stabilizer, at lease one antiobiotic or an additional active ingredient.

21. A vaccine composition comprising an effective amount of the recombinant polypeptide of claim 18 and a pharmaceutically acceptable carrier.

22. The vaccine composition of claim 21 , further comprising one or more of an adjuvant, a preservative, a stabilizer, at lease one antiobiotic or an additional active ingredient.

23. A method to distrupt or preserve the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 22 .

24. A method to distrupt or preserve the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 21 .

25. A method to distrupt or preserve the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the polypeptide of claim 18 .

Continuity (4)
Provisional Application 62455437 · Feb 6, 2017
Provisional Application 62453921 · Feb 2, 2017
Provisional Application 62442307 · Jan 4, 2017
Related Publication 20190337996A1 · Nov 7, 2019
Cited By (1)
US 12,239,763